Research Projects Page

Immunomodulatory therapies for multiple myeloma can increase patient risk for venous thromboembolism (VTE). This phase IV single-arm study assessed the rate of symptomatic VTE over 6 months in 50 patients with multiple myeloma receiving immunomodulatory therapy and apixaban for primary prevention. No patients experienced symptomatic VTE or a major hemorrhage and 3 patients experienced clinically relevant non-major hemorrhage but were able to resume apixaban after medical management.

The purpose of this initiative was to develop a tool to assess quality in the use of TKIs to manage NSCLC and ultimately track variables such as proper medication use, patient safety and healthcare resource utilization.

The purpose of this study was to assess medication non-adherence [defined as medication possession ratio (MPR)]and validate the findings of risk factors for non-adherence to biologic therapy for adult inflammatory bowel disease: narcotic use, psychiatric diagnosis history, prior biologic use, and smoking. This study found that previously identified cumulative risk factors remain significant.

The objective of this study was to better define the association of hepatitis C-positive donors with heart transplant volumes, wait-list duration, and mortality at 1 year. Findings suggest that infection is well-tolerated and curable in heart transplant recipients with donor-derived hepatitis C, and 1-year survival is equivalent to that in recipients of hepatitis C-negative donors.

This study looked at 21 acute myeloid leukemia patients who had received a hematopoietic cell transplant and experienced relapsed disease. Each patient underwent salvage therapy with a venetoclax- based treatment regimen. Nineteen patients were assessed for treatment response and 12 of the 19 patients responded to venetoclax-based salvage therapy, leading to a 63.2% response rate.

In this initiative, we evaluated outcomes following prescription of specialty dermatology medications in biologic-naïve patients. Of the 28 prescriptions evaluated, median time to approval was 9 days, with delays resulting from the need for a pharmacist to ascertain clinical data such as disease severity and treatment history.

This study evaluated reasons for nonadherence in a random 10% sample of the patients identified as nonadherent (PDC less than 80%) from the study below. We found that 40% of patients classified as nonadherent were misclassified, with 31% of those due to external fills, and 60% due to provider-recommended gaps in therapy. Most cases of true nonadherence were due to an inability to reach the patient.

In this ambispective cohort study of patients referred to an outpatient Infectious Diseases Clinic for chronic HCV, we found significant differences in patient demographics, drug interactions, and time to treat between HCV monoinfected and HIV/HCV coinfected patients. This study provides a broad, yet concise overview of the differences in caring for patients with and without HIV/HCV coinfection.

In the Southern US, HIV prevalence is disproportionately high and PrEP use is disproportionately low. This cross-sectional survey study assessed Tennessee primary care providers’ current PrEP knowledge, attitudes, and prescribing practices with the aim to determine barriers to PrEP provision specific to TN providers.

Ivosidenib is the first approved oral, targeted, small molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) mutation seen in acute myeloid leukemia. This review article discusses the clinical trials and dose escalation studies conducted to secure the U.S. Food and Drug Administration approval.